Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced the appointment of Martha Shadan to its Board of Directors. Shadan brings over 30 years of leadership experience in the life sciences sector, having held key positions at various notable firms, including Miach Orthopaedics and Smith & Nephew. She expressed her commitment to advancing CVRx's innovative therapies, particularly the FDA-approved Barostim device for heart failure patients, which aims to enhance cardiovascular health.
CVRx, a medical technology company, successfully priced its initial public offering (IPO) at $18.00 per share, raising approximately $126 million. The IPO allows for an additional 1,050,000 shares underwriters can purchase. CVRx specializes in solutions for heart failure, notably its Barostim Neo™, the first neuromodulation device for heart failure and the first medical device to receive the FDA's Breakthrough Device Designation. Trading under the ticker symbol 'CVRX' began on June 30, 2021, with J.P. Morgan and others serving as underwriters.
CVRx, Inc. has successfully closed its initial public offering (IPO) of 8,050,000 shares of common stock at $18.00 per share, generating approximately $144.9 million in gross proceeds. This includes an additional 1,050,000 shares exercised by underwriters. The stock began trading on Nasdaq under the ticker CVRX on June 30, 2021. The IPO was facilitated by J.P. Morgan, Piper Sandler, and William Blair as joint book-running managers.